Compare Enphase Energy Inc (ENPH) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Incyte Corporation — how do they compare? Enphase Energy Inc trades at $42.25 (market cap $5.81B), while Incyte Corporation trades at $116.23 (market cap $22.99B). The key difference: Incyte Corporation is far larger — about 4× Enphase Energy Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.
| ENPH | INCY | |
|---|---|---|
Market Cap | $5.81B | $22.99B |
Sector | Technology | Health |
52-Week High | $72.33 | $118.52 |
52-Week Low | $26.12 | $67.38 |
Enterprise Value | $5.46B | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $44.985, up 4.47% with a neutral technical signal despite bullish moving averages. The company has beaten earnings expectations for three consecutive quarters, though revenue declined from $2.3B in 2023 to $1.47B in 2025. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $42.79 below current levels. Recent news highlights product expansions in Europe and Australia alongside ongoing legal scrutiny.
ENPH faces near-term headwinds with declining revenue and compressed margins, but maintains strong profitability metrics and consistent earnings beats. Investment appeal hinges on international growth execution and potential regulatory tailwinds, balanced against competitive pressures and stock volatility. The current valuation at 43.61 P/E requires robust growth reinstatement to justify upside.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
